Article
Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer
1 Jan 2023
Abstract excerpt
Advanced prostate cancer patients initially respond to hormone therapy, be it in the form of androgen deprivation therapy or second-generation hormone therapies, such as abiraterone acetate or enzalutamide. However, most men with prostate cancer eventually develop hormone therapy resistance. This resistance can arise through multiple mechanisms, such as through genetic mutations, epigenetic mechanisms, or through...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
